论文部分内容阅读
目的:对制备的LETMD1-C末端单克隆抗体进行免疫特性鉴定,并将其应用于肝细胞癌的临床诊断研究。方法:使用ELISA,细胞免疫荧光及Western blot等免疫学技术对所制备的单克隆抗体进行免疫特性鉴定;以鉴定的抗体为工具,检测肝癌组织中LETMD1编码产物表达情况。结果:免疫学鉴定结果验证了制备的单克隆抗体具有较高的使用效价和良好的特异性。检测肝组织标本中LETMD1编码产物表达情况,发现其在正常组织中不表达,在肝癌组织表达明显高于癌旁组织。结论:制备了抗-LETMD1-C末端的单克隆抗体,经鉴定具有较高的效价和良好的特异性,可以应用于LETMD1癌基因的功能研究和肝细胞癌的临床诊断研究,为深入研究LETMD1蛋白的生物学功能和建立新的肝细胞癌早期诊断方法奠定了可靠基础。
OBJECTIVE: To characterize the immunogenicity of the prepared LETMD1-C terminal monoclonal antibody and to apply it in the clinical diagnosis of hepatocellular carcinoma. Methods: The immunological characteristics of the prepared monoclonal antibodies were identified by ELISA, immunofluorescence and Western blot. The identified antibodies were used as tools to detect the expression of LETMD1 in hepatocellular carcinoma tissues. Results: The results of immunological tests confirmed that the prepared monoclonal antibody has high potency and good specificity. The expression of LETMD1 was detected in liver samples and found that it was not expressed in normal tissues and was significantly higher in HCC tissues than in paracancerous tissues. CONCLUSION: Monoclonal antibodies against LETMD1-C terminus have been identified and have high potency and good specificity. They can be used in functional studies of LETMD1 oncogene and clinical diagnosis of hepatocellular carcinoma. In order to further study LETMD1 protein biological function and the establishment of a new method of early diagnosis of hepatocellular carcinoma laid a solid foundation.